12
Participants
Start Date
June 30, 2012
Primary Completion Date
March 31, 2015
Study Completion Date
October 31, 2015
Lenalidomide
"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
Universitätsklinik der PMU Salzburg, Univ-Klinik für Innere Medizin III, Salzburg
Universitätsklinik für Innere Medizin Innsbruck, Klinische Abteilung für Hämatologie und Onkologie, Innsbruck
Collaborators (1)
Celgene
INDUSTRY
Arbeitsgemeinschaft medikamentoese Tumortherapie
OTHER